title: Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade.
abstract: OBJECTIVE
  Clinical studies indicate that the remission, regression or both of nephrotic-range albuminuria are exerted by angiotensin II receptor blockers (ARBs) in diabetes. The current study was performed to test the hypothesis that these effects of ARBs are associated with regression of glomerular podocyte injury.
  
  
  METHODS
  We examined the effects of an ARB, olmesartan, on glomerular podocyte injury in type 2 diabetic Otsuka-Long-Evans-Tokushima-Fatty rats with overt albuminuria.
  
  
  RESULTS
  At baseline (55-week-old), diabetic Otsuka-Long-Evans-Tokushima-Fatty rats showed severe albuminuria with desmin-positive areas (an index of podocyte injury) in both superficial and juxtamedullary glomeruli, and podocyte injury was much greater in juxtamedullary than in superficial glomeruli. At 75-week-old, Otsuka-Long-Evans-Tokushima-Fatty rats had developed more severe albuminuria and superficial glomerular podocyte injury, whereas juxtamedullary glomerular podocyte injury did not advance further. Olmesartan (10 mg/kg per day) decreased albuminuria and superficial glomerular desmin staining to levels that were lower than those at baseline, whereas advanced juxtamedullary glomerular podocyte injury was not changed.
  
  
  CONCLUSIONS
  The current study demonstrates for the first time that juxtamedullary glomerular podocyte injury reaches a severe condition at an earlier time than superficial glomerular podocyte injury during the progression of overt albuminuria in type 2 diabetic rats. Our data also support the hypothesis that the antialbuminuric effects of ARBs are associated with regression of superficial glomerular podocyte injury in type 2 diabetes with nephrotic-range albuminuria.
authors: Cardiorenal and Cerebrovascular Internal Medicine, Kagawa University Medical School, Kagawa, Japan.
authors: Genei
authors: G
authors: Ihara
authors: Hideyasu
authors: H
authors: Kiyomoto
authors: Hiroyuki
authors: H
authors: Kobori
authors: Yukiko
authors: Y
authors: Nagai
authors: Naro
authors: N
authors: Ohashi
authors: Hirofumi
authors: H
authors: Hitomi
authors: Daisuke
authors: D
authors: Nakano
authors: Nicolas
authors: N
authors: Pelisch
authors: Taiga
authors: T
authors: Hara
authors: Takefumi
authors: T
authors: Mori
authors: Sadayoshi
authors: S
authors: Ito
authors: Masakazu
authors: M
authors: Kohno
authors: Akira
authors: A
authors: Nishiyama
mesh_terms: D000419:Albuminuria / Q000473:pathology*; D000804:Angiotensin II / Q000378:metabolism*; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000628:therapy*; D004195:Disease Models, Animal; D007668:Kidney / Q000473:pathology; D007678:Kidney Glomerulus / Q000473:pathology; D008297:Male; D050199:Podocytes / Q000473:pathology; D051381:Rats; D020318:Rats, Long-Evans; D012074:Remission Induction; D012598:Sclerosis / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000804:Angiotensin II